Regional differences in cardiovascular risk factor profile cannot fully explain differences in cardiovascular morbidity in the Netherlands: A comparison of two urban areas

Netherlands Journal of Medicine

Volumn 63, Issue 8, 2005, Pages 309-315

  Plat, Arian W ^a,b   te Wierik, M J M ^a   Kroon, A A ^b   Schouten, H J A ^a   van den Akker, M ^a   van Schayck, C P ^a   de Leeuw, P W ^b   Hajema, K J ^c   Stoffers, H E J H ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Public Health Service South Limburg   (Netherlands)

Author keywords

Cardiovascular diseases mortality; Morbidity prevalence; Netherlands epidemiology; Risk factors

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; INFORMATION RETRIEVAL; INTERNATIONAL CLASSIFICATION OF DISEASES; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NETHERLANDS; OBESITY; POPULATION RESEARCH; PREVALENCE; PRIMARY MEDICAL CARE; REGISTER; RISK FACTOR; STANDARDIZATION; URBAN AREA;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DEATH CERTIFICATES; FEMALE; GEOGRAPHY; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PREVALENCE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; URBAN HEALTH;

EID: 26044441152     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Henskens LH, Spiering W, Stoffers HE, Soomers FL, Vlietinck RF, de Leeuw PW, et al. Effects of ACE I/D and AT1R-A1166C polymorphisms on blood pressure in a healthy normotensive primary care population: first results of the Hippocrates study. J Hypertens 2003;21(1):81-6.
2. Metsemakers JF, Hoppener P, Knottnerus JA, Kocken RJ, Limonard CB. Computerized health information in the Netherlands: a registration network of family practices. Br J Gen Pract 1992;42(356):102-6.
3. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000;355(9205):675-87.
4. Nawawi HM, Nor IM, Noor IM, Karim NA, Arshad F, Khan R, et al. Current status of coronary risk factors among rural Malays in Malaysia. J Cardiovasc Risk 2002;9(1):17-23.
5. WHO. ICD-10: International statistical classification of diseases and related health problems. 10th ed. Geneva: World Health Organization; 1992.
6. Mackenbach JP, Van Duyne WM, Kelson MC. Certification and coding of two underlying causes of death in the Netherlands and other countries of the European Community. J Epidemiol Community Health 1987;41(2):156-60.
7. Schadé B. Reliability and validity of the classification of death in general practice. Scand J Prim Health Care 1987;5(2):109-12.
8. Metsemakers JFM. Unlocking patients' records in general practice for research, medical education and quality assurance. Maastricht: Rijksuniversiteit Limburg; 1994.
9. Lamberts H, Wood M, editors. ICPC: International Classification of Primary Care. Oxford: Oxford University Press; 1987.
10. Classification Committee of Wonca. Oxford: Oxford University Press; 1983.
11. van den Akker M, Franssen GHLM, Buntinx F, Metsemakers JFM, Knottnerus JA. The reliability of register-based patient characteristics. Archives of Public Health 1997;55:231-38.
12. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: John Wiley and Sons; 2000. pp 147-156.
13. Mackenbach JP, Snels IA, Friden-Kill LM. Diabetes mellitus as cause of death. Ned Tijdschr Geneeskd 1991;135(33):1492-6.
14. Kircher T, Nelson J, Burdo H. The autopsy as a measure of accuracy of the death certificate. N Engl J Med 1985;313(20):1263-9.
15. Messite J, Stellman SD. Accuracy of death certificate completion: the need for formalized physician training. Jama 1996;275(10):794-6.
16. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976;38(1):46-51.
17. Mackenbach JP, Kunst AE, Looman CW. Cultural and economic determinants of geographical mortality patterns in The Netherlands. J Epidemiol Community Health 1991;45(3):231-7.
18. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337(4):230-6.
19. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1999;159(1):38-44.
20. van der Bom JG, Bots ML, Grobbee DE. Cardiovascular risk factors. Review of possible causes of heart and vascular diseases. Ned Tijdschr Geneeskd 2002;146(25):1169-74.
21. van der Griend R, Biesma DH, Banga JD. Hyperhomocysteinaemia as a cardiovascular risk factor: an update. Neth J Med 2000;56(3):119-30.
22. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10(4):S1-S10.
23. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356(9246):1955-64.
24. Sing CF, Stengard JH, Kardia SL. Genes, environment, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2003;23(7):1190-6.
25. Smilde TJ, van Wissen S, Wollersheim H, Kastelein JJ, Stalenhoef AF. Genetic and metabolic factors predicting risk of cardiovascular disease in familial hypercholesterolemia. Neth J Med 2001;59(4):184-95.
26. Wang JG, Staessen JA. Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease. Eur J Pharmacol 2000;410(2-3):289-302.
27. Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW, et al. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 2002;20(10):2023-7.
28. Spiering W, Kroon AA, Vreugdenhil HA, Geraedts JP, Daemen MJ, de Leeuw PW. [The relationship between genetic polymorphisms and disease, illustrated by the renin-angiotensin-aldosterone system and cardiovascular disease]. Ned Tijdschr Geneeskd 1998;142(25):1445-50.
29. Spiering W, Kroon AA, Fuss-Lejeune MM, Daemen MJ, de Leeuw PW. Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet. Hypertension 2000;36(3):411-6.
30. Tiret L. Gene-environment interaction: a central concept in multifactorial diseases. Proc Nutr SOC 2002;61(4):457-63.
31. Stephens JW, Humphries SE. The molecular genetics of cardiovascular disease: clinical implications. J Intern Med 2003;253(2):120-7.
32. Herrmann SM, Paul M. Studying genotype-phenotype relationships: cardiovascular disease as an example. J Mol Med 2002;80(5):282-9.
33. D'Orleans-Juste P, Plante GE. ACE Inhibitors. Basel, Switzerland: Birkhäuser Verlag; 2001. pp. 11-27.